HUB Organoid Technology (HUB)
Hubrecht Organoid Technology (HUB) is a pioneering organization spun off from the Hubrecht Institute in the Netherlands, recognized for its world-leading, patented Organoid Technology originally developed by Prof. Hans Clevers. As one of the earliest organizations to commercialize these models, HUB has established a paradigm-shifting platform for pre-clinical patient stratification and personalized medicine. The company’s core offering is its “living biobanks” of patient-derived organoids (PDOs), which are 3D in vitro structures grown from adult stem cells. These models faithfully recapitulate the phenotypic and genetic features of the original tumor or tissue, including crucial details like patient-specific genetic mutations. HUB offers licenses to its technology and provides customized drug screening services across therapeutic areas like oncology, toxicology, and inflammation. By providing a scalable, genetically stable, and clinically-relevant model system, HUB helps pharmaceutical companies accelerate target validation and develop targeted therapies with improved translational potential.
Latest Market Research Report on Human Organoids Download PDF Brochure Now
Thermo Fisher Scientific Inc.
Thermo Fisher Scientific is a globally renowned leader in the scientific solutions and healthcare sectors, playing a foundational role in the Human Organoids market. The company’s expansive portfolio ensures it serves as an essential, end-to-end supplier for the infrastructure required to grow, maintain, and analyze organoid models. Thermo Fisher significantly contributes by providing advanced instruments, a vast array of high-quality reagents, and essential consumables necessary for the entire organoid workflow. Their offerings include specialized cell culture plastics, optimized media and matrices (like those used for 3D culture), and high-throughput imaging systems (e.g., High Content Imaging) crucial for analyzing organoid phenotypes, growth, and drug responses. The company’s commitment to integrating its technology into scalable systems allows researchers to reliably perform large-scale drug screens on tumor organoids and conduct fundamental studies in developmental biology and disease modeling, thereby accelerating breakthroughs in human-relevant research.
Merck KGaA
Merck KGaA is a leading German science and technology company that has cemented its position in the Human Organoids market primarily through strategic acquisition and internal R&D. The company significantly expanded its footprint by acquiring HUB Organoids Holding B.V., thereby integrating the world-leading, patented Hubrecht Organoid Technology and its extensive biobank of patient-derived organoids (PDOs) into its Life Science business. This move allowed Merck to offer a comprehensive portfolio of services and products, from the basic chemical and biological tools for organoid culture to advanced drug screening utilizing PDOs for predictive diagnostics. Furthermore, Merck KGaA is actively investing in the research and development of next-generation organoids, specifically focusing on integrating these models with chip technology to create miniaturized, automated, and more complex systems for high-throughput applications, driving forward the shift towards advanced human-relevant testing.
Emulate
Emulate is an innovative life science company that has emerged as a key player by pioneering the application of microfluidics to create advanced Organ-on-a-Chip (OOC) systems, which are highly dynamic, functional organoid models. The company’s flagship offering, the Human Emulation System, uses a microfluidic platform to precisely replicate the complex mechanical and biochemical functions of human organs, including liver, lung, kidney, and brain models, on a microchip. These systems are significantly more predictive than traditional static 2D cultures and animal models. By simulating realistic cellular microenvironments and dynamic blood flow within microfluidic channels, Emulate’s OOC systems enhance preclinical testing for drug toxicity and disease modeling. The company actively collaborates with regulatory bodies and major pharmaceutical companies to integrate this powerful platform into the drug discovery pipeline, driving the shift toward personalized medicine and more effective therapeutic product development.
InSphero
InSphero, a Swiss company, is a prominent developer in the 3D microtissue and organoid space, known for providing standardized, high-quality models for drug discovery and safety testing. While they specialize in scaffold-free 3D microtissues, their technology directly augments the Human Organoids field. Their Akura™ Flow system is designed to integrate microfluidic channels, which maintains physiologically relevant conditions for organoids and microtissues by simulating tissue-level nutrient exchange. InSphero’s models, such as their liver-on-a-chip and pancreatic islet models, are critical tools in studies related to metabolic diseases and drug-induced liver injuries (DILI). These 3D structures possess crucial characteristics, including cell-cell interactions and functional capacity, that are more representative of human tissue than traditional 2D systems, making them highly valuable for toxicology and efficacy screening in a reproducible and scalable format.
Mimetas
Mimetas, based in the Netherlands, is a key developer of dynamic, perfused 3D cell culture systems that are essential for the next generation of organoid research. The company’s flagship product, the OrganoPlate® platform, is a microfluidic system that allows scientists to grow 3D human tissues and organoids under controlled, dynamic flow conditions. This platform enables the co-culture of multiple cell types and the creation of tissue-to-tissue interfaces, closely mimicking the native *in vivo* environment, which is a major advantage over static organoid cultures. The OrganoPlate is widely utilized for high-throughput drug screening, toxicity assessment, and complex disease modeling. Notably, Mimetas has developed specialized models, such as the blood-brain barrier-on-a-chip, which provide highly relevant tools for neurological drug development and other studies requiring precise simulation of human tissue architecture and function.
STEMCELL Technologies Inc.
STEMCELL Technologies, a Canadian global biotechnology company, is a crucial enabler in the Human Organoids market as a market leader in providing specialized and high-quality cell culture consumables. While not a model developer, the company supplies the fundamental tools required for the successful growth and maintenance of organoids. STEMCELL Technologies develops and provides optimized, GMP-compliant organoid culture media, kits, and specialized extracellular matrices (ECMs), which are essential for directing the differentiation and self-organization of stem cells into 3D organoid structures. Their products support the development of various human organoid types, including intestinal, hepatic, and neural models, derived from both adult stem cells and pluripotent stem cells (PSCs). By offering standardized, robust, and reliable reagents, the company facilitates the reproducibility and scalability of organoid cultures for research, drug discovery, and large-scale clinical banking.
ATCC
The American Type Culture Collection (ATCC) is a global biological resource center that plays a vital role in standardizing and distributing high-quality organoid models to the scientific community. ATCC actively offers next-generation, patient-derived organoids (PDOs), particularly through a collaboration with the Human Cancer Models Initiative (HCMI). These PDOs are derived from human cancer patients and are rigorously characterized, retaining the diverse genetic backgrounds and clinical data of the original tumors, which is crucial for translational research. To support widespread adoption, ATCC provides researchers with not only the authenticated organoid models but also the necessary organoid growth kits and comprehensive protocols for their subculture and maintenance. By ensuring high authenticity, quality control, and accessibility of these models, ATCC accelerates cancer research and drug screening by offering reliable, human-relevant 3D culture tools.
Crown Bioscience
Crown Bioscience, a global Contract Research Organization (CRO), is a significant service provider in the Human Organoids market, offering an integrated platform for preclinical drug discovery and validation. The company holds a key position through its exclusive license from Hubrecht Organoid Technology (HUB) to provide oncology drug development services using HUB’s patient-derived organoids (PDOs). CrownBio’s OrganoidBase™ is an extensive biobank of tumor organoid models derived from both patients and its own patient-derived xenograft (PDX) models. The company leverages this resource to provide drug screening services that evaluate efficacy, toxicity, and drug combinations in a clinically-relevant, high-throughput format. By combining its organoid platform with its existing portfolio of *in vivo* models and drug discovery expertise, Crown Bioscience helps pharmaceutical clients transition from in vitro testing to animal-based validation seamlessly, fast-tracking the selection of clinical candidates.
DefiniGEN
DefiniGEN is a UK-based biotechnology company that specializes in creating highly functional and disease-specific human organoids using induced pluripotent stem cell (iPSC) technology. The company’s core strategy is to provide genetically accurate, human-relevant cell products for use in drug discovery and safety testing, particularly targeting complex therapeutic areas. DefiniGEN focuses on generating robust models for metabolic and liver diseases, such as advanced liver and intestinal organoids. By leveraging its proprietary iPSC platform, DefiniGEN ensures its organoids are functionally mature and highly characterized, offering a superior model for studying disease mechanisms, drug toxicity (like drug-induced liver injury or DILI), and compound efficacy. The use of these genetically accurate, iPSC-derived models helps researchers gain more predictive insights, effectively addressing the need for better models that close the translational gap in the drug development pipeline.
Latest Market Research Report on Human Organoids Download PDF Brochure Now